Study of the Medication Prazosin for Alcohol Dependence

• Status: Completed
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether the drug prazosin is effective for the treatment of alcohol dependency.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seattle Institute for Biomedical and Clinical Research
• Collaborators: National Institute on Alcohol Abuse and Alcoholism (NIAAA); University of Washington; VA Puget Sound Health Care System
• Treatments: Ethanol; Prazosin

Criteria

Inclusion Criteria:

• Current primary DSM-IV diagnosis of alcohol dependence(AD)

• Heavy drinking in the last 30 days

• At least 18 years of age

• Good general medical health (see Exclusion Criteria below)

• Capacity to provide informed consent

• English fluency and literacy

Exclusion Criteria:

• Psychiatric/behavioral: current post-traumatic stress disorder(PTSD); psychiatric disorder requiring any medication other than anti-depressants; currently taking disulfiram, acamprosate, or naltrexone or planning to take any of these medications during the 12-week medication phase of the study; current dependence on any other psychoactive substance other than nicotine or cannabis; a current diagnosis of opioid abuse, use of any opioid- containing medications or benzodiazepines during the previous month, or UDA positive for opioids, benzodiazepines, or sedative hypnotics.

• Medical: significant acute or chronic medical illness; women who are pregnant, nursing infant(s), or of childbearing potential and not using a contraceptive method judged by the study physician or PA to be effective; signs or symptoms of alcohol withdrawal at the time of initial consent

• Legal involvement that could interfere with study treatment. Individuals court ordered for treatment will not be eligible to participate in this study.